Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
QuintilesIMS
Chinese Patent Office
US Army
Citi
AstraZeneca
Dow
Deloitte

Generated: July 15, 2018

DrugPatentWatch Database Preview

TESLAC Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Teslac, and when can generic versions of Teslac launch?

Teslac is a drug marketed by Bristol Myers Squibb and is included in two NDAs.

The generic ingredient in TESLAC is testolactone. There are two drug master file entries for this compound. Additional details are available on the testolactone profile page.
Summary for TESLAC
Drug patent expirations by year for TESLAC
Medical Subject Heading (MeSH) Categories for TESLAC
Synonyms for TESLAC
.DELTA.1-Dehydrotestolactone
.DELTA.1-Dehydrotestololactone
.DELTA.1-Testololactone
(1R,2S,7S,10S,11R)-7,11-DIMETHYL-6-OXATETRACYCLO[8.8.0.0(2),?.0(1)(1),(1)?]OCTADECA-12,15-DIENE-5,14-DIONE
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
1 Dehydrotestolactone
1-Dehydrotestolactone
1-Dehydrotestololactone
1,2-Dehydrotestololactone
1,2-Didehydrotestololactone
1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone
13-Hydroxy-3-oxo-13,4-dien-17-oic acid .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI)
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
13,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
17a-Oxa-D-homoandrosta-1,17-dione
17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione
17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione
2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
2H-Phenanthro[2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
6J9BLA949Q
968-93-4
968T934
AB0106302
AC1L22FS
AKOS015840139
BDBM50367848
Bristol Myers SquibbBrand of Testolactone
Bristol-Myers Squibb Brand of Testolactone
C-23729
C02197
C19H24O3
CAS-968-93-4
CC-34814
CHEBI:9460
CHEMBL1571
CS-5268
D-Homo-17a-oxaandrosta-1,17-dione
D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione
D00153
D0C7JF
DB00894
Delta-1-testololactone
delta(1)-Dehydrotestolactone
delta(1)-Testolactone
delta(1)-Testololactone
delta1-Dehydrotestolactone
delta1-Dehydrotestololactone
delta1-Testololactone
DR001195
DSSTox_CID_3644
DSSTox_GSID_23644
DSSTox_RID_77126
DTXSID2023644
EINECS 213-534-6
Fludestrin
GTPL7303
HSDB 3255
HY-13763
LMST02020084
LS-102968
NCGC00159329-02
NCI60_001908
NSC 12173
NSC 23759
NSC-12173
NSC-23759
NSC23759
PL076192
SC-18054
SCHEMBL4053
SQ 9538
SQ-9538
Teolit
TESLAC (TN)
Teslak
Testolacton
Testolactona
Testolactona [INN-Spanish]
testolactone
Testolactone (USP/INN)
Testolactone [USAN:INN]
Testolactone [USAN:USP:INN]
Testolactonum
Testolactonum [INN-Latin]
Testolattone
Testolattone [DCIT]
Testololactone, 1-dehydro-
Testololactone, 1,2-didehydro-
Testololactone,2-didehydro-
Tox21_111576
UNII-6J9BLA949Q
W-100129
ZINC4081771

US Patents and Regulatory Information for TESLAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb TESLAC testolactone INJECTABLE;INJECTION 016119-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb TESLAC testolactone TABLET;ORAL 016118-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb TESLAC testolactone TABLET;ORAL 016118-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Farmers Insurance
Chubb
Merck
Johnson and Johnson
Cantor Fitzgerald
Teva
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.